Search / Trial NCT00000374

Treatment for First-Episode Schizophrenia

Launched by NORTHWELL HEALTH · Nov 2, 1999

Apply for Trial

Trial Information

Current as of March 05, 2024

Completed

Keywords

Adolescence Adult Antipsychotic Agents Female Human Male Olanzapine Risperidone Schizophrenia Antipsychotic Agents *Therapeutic Use Olanzapine *Therapeutic Use Risperidone *Therapeutic Use Schizophrenia *Drug Therapy

Description

The goal of the study is to prevent morbidity in first-episode schizophrenia using second-generation antipsychotic drugs: olanzapine, risperidone. Long-term studies of first-episode schizophrenia patients have clearly indicated excellent initial responsiveness of positive psychotic symptoms to treatment with conventional antipsychotic medications. However, in the years immediately following this initial good response, morbidity increases. Relapses, often multiple ones, are the rule and are usually precipitated by medication noncompliance. There is some evidence that the second-generation a...

Gender

All

Eligibility criteria

  • Inclusion Criteria:
  • First episode schizophrenia, schizophreniform disorder or schizoaffective disorder
  • Exclusion Criteria:
  • Prior treatment with antipsychotic medications.

Attachments

readout_NCT00000374_2024-03-05.pdf

4.5 MB

NCT00000374_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bronx, New York, United States

Glen Oaks, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

8 consecutive weeks

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0